Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning

European Respiratory Journal

Volumn 54, Issue 6, 2019, Pages

  König, Rainer ^a,b   Cao, Xueqi ^a,b   Oswald, Marcus ^a,b   Forstner, Christina ^a,c   Rohde, Gernot ^d,e,f   Rupp, Jan ^e,g   Witzenrath, Martin ^e,h   Welte, Tobias ^e   Kolditz, Martin ⁱ   Pletz, Mathias ^a,e  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b HANS KNÖLL INSTITUTE   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f German Center for Lung Research   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^j Center for Infectious Diseases and Infection Control ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

MACROLIDE; ANTIINFECTIVE AGENT; BETA LACTAM;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMMUNITY ACQUIRED PNEUMONIA; DECISION TREE; FEMALE; HOSPITALIZATION; HUMAN; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; OBSERVATIONAL STUDY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMMUNITY ACQUIRED INFECTION; EUROPE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROPENSITY SCORE; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HOSPITALIZATION; HUMANS; MACHINE LEARNING; MACROLIDES; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROPENSITY SCORE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85076446359     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00824-2019     Document Type: Article

References (37)

1. Remington LT, Sligl WI. Community-acquired pneumonia. Curr Opin Pulm Med 2014; 20: 215-224.
2. Welte T, Suttorp N, Marre R. CAPNETZ - Community-Acquired Pneumonia Competence Network. Infection 2004; 32: 234-238.
3. Almirall J, Bolíbar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000; 15: 757-763.
4. Ewig S, Bauer T, Richter K, et al. Prediction of in-hospital death from community-acquired pneumonia by varying CRB-age groups. Eur Respir J 2013; 41: 917-922.
5. Welte T. Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality. Eur J Clin Microbiol Infect Dis 2012; 31: 33-47.
6. Cheng YJ, Nie XY, Chen XM, et al. The role of macrolide antibiotics in increasing cardiovascular risk. J Am Coll Cardiol 2015; 66: 2173-2184.
7. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010; 23: 590-615.
8. Blondeau JM, DeCarolis E, Metzler KL, et al. The macrolides. Expert Opin Investig Drugs 2002; 11: 189-215.
9. Owens RC, Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006; 43: 1603-1611.
10. Nie W, Li B, Xiu Q. β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J Antimicrob Chemother 2014; 69: 1441-1446.
11. Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015; 372: 1312-1323.
12. Garin N, Genné D, Carballo S, et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 2014; 174: 1894-1901.
13. Suttorp N, Welte T, Marre R, et al. Das Kompetenzzentrum für ambulant erworbene Pneumonie. [CAPNETZ. The competence network for community-acquired pneumonia (CAP)]. Bundesgesundheitsblatt Gesundheitsforschung, Gesundheitsschutz 2016; 59: 475-481.
14. Forstner C, Rohde G, Rupp J, et al. Community-acquired Haemophilus influenzae pneumonia - new insights from the CAPNETZ study. J Infect 2016; 72: 554-563.
15. Bartlett RC. Medical Microbiology: Quality, Cost and Clinical Relevance. New York, John Wiley & Sons, 1974; pp. 24-31.
16. Zobel K, Martus P, Pletz MW, et al. Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from the German competence network CAPNETZ. BMC Pulm Med 2012; 12: 6.
17. Ho DE, Imai K, King G, et al. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Soft 2011; 42: 1-28.
18. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011; 10: 150-161.
19. Kuss O, Blettner M, Börgermann J. Propensity score: an alternative method of analyzing treatment effects. Dtsch Arztebl Int 2016; 113: 597-603.
20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JR Stat Soc Series B Methodol 1995; 57: 289-300.
21. Albert RK, Schuller JL. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med 2014; 189: 1173-1180.
22. Bril F, Gonzalez CD, Di Girolamo G. Antimicrobial agents-associated with QT interval prolongation. Curr Drug Saf 2010; 5: 85-92.
23. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366: 1881-1890.
24. Hancox JC, Hasnain M, Vieweg WV, et al. Erythromycin, QTc interval prolongation, and torsade de pointes: case reports, major risk factors and illness severity. Ther Adv Infect Dis 2014; 2: 47-59.
25. Ceccato A, Cilloniz C, Martin-Loeches I, et al. Effect of combined β-lactam/macrolide therapy on mortality according to the microbial etiology and inflammatory status of patients with community-acquired pneumonia. Chest 2019; 155: 795-804.
26. Gottlieb J, Szangolies J, Koehnlein T, et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008; 85: 36-41.
27. Zimmermann P, Ziesenitz VC, Curtis N, et al. The immunomodulatory effects of macrolides - a systematic review of the underlying mechanisms. Front Immunol 2018; 9: 302.
28. Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis 2018; 12: 1753465817750524.
29. Dumke R, Schnee C, Pletz MW, et al. Mycoplasma pneumoniae and Chlamydia spp. infection in community-acquired pneumonia, Germany, 2011-2012. Emerging Infect Dis 2015; 21: 426-434.
30. von Baum H, Welte T, Marre R, et al. Mycoplasma pneumoniae pneumonia revisited within the German Competence Network for Community-acquired pneumonia (CAPNETZ). BMC Infect Dis 2009; 9: 62.
31. Naderi N, Assayag D, Mostafavi-Pour-Manshadi SM, et al. Long-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary disease. Respir Med 2018; 138: 129-136.
32. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-1147.
33. Efthimiadis A, Spanevello A, Hamid Q, et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl 2002; 37: 19s-23s.
34. Park HJ, Woo A, Cha JM, et al. Closed-type pre-treatment device for point-of-care testing of sputum. Sci Rep 2018; 8: 16508.
35. Gorelik E, Masarwa R, Perlman A, et al. Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides. Antimicrob Agents Chemother 2018; 62: e00438-18.
36. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991; 91: 40S-45S.
37. Amsden GW. Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther 1996; 18: 56-72.